Assertio Therapeutics Announces Appointment of Heather L. Mason to Board of Directors

February 19, 2019

LAKE FOREST, Ill., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that Heather L. Mason has been appointed to the Company's Board of Directors. Ms. Mason is a former executive vice president of Abbott Laboratories.

"Heather is an accomplished business leader with nearly 30 years of healthcare experience," said Arthur Higgins, President and CEO of Assertio. "Heather adds depth to our Board of Directors and brings invaluable pharmaceutical experience to Assertio. We're fortunate to have someone of her caliber join our Board."

"It's a privilege to serve on Assertio's Board," said Ms. Mason. "I am excited about the future of Assertio and I'm confident that we're focusing on the right initiatives to drive shareholder value."

Ms. Mason, 58, is a former senior executive of Abbott Laboratories, having recently retired as Executive Vice President of Abbott Nutrition. Ms. Mason also served as Executive Vice President, Global Commercial Operations at Abbott and Senior Vice President of Abbott Diabetes Care. Ms. Mason joined Abbott in 1990 and held positions in Abbott's U.S. pharmaceutical business, including oversight of Abbott's specialty pharmaceuticals, its diabetes/metabolics and oncology franchises, and managed health care. Ms. Mason also served as Vice President, International Marketing, and Vice President, Latin American Operations, in Abbott's international pharmaceutical business. Prior to joining Abbott, Ms. Mason worked for Quaker Oats, FMC Corporation, and Commonwealth Edison. Ms. Mason holds a B.S.E. in Industrial Engineering from the University of Michigan and a M.B.A. from the University of Chicago.

The Company also announced today that Louis J. Lavigne, Jr. notified the Board that he is retiring from the Board at the end of his current term and therefore would not stand for re-election to the Board at the Company's 2019 Annual Meeting of Stockholders. Mr. Lavigne is expected to continue to serve as a director until the expiration of his current term, which ends effective upon the election of directors at the Annual Meeting.

"On behalf of the Board and Assertio, we welcome Heather and we would like to thank Lou for his many contributions to our company," said James P. Fogarty, Assertio's Chairman of the Board. "Lou has provided a breadth of expertise in strategy, finance and operations. We wish him the very best."

About Assertio Therapeutics, Inc.
Assertio Therapeutics is committed to providing responsible solutions to advance patient care in the Company's core areas of neurology, orphan and specialty medicines. Assertio currently markets three FDA-approved products and continues to identify, license and develop new products that offer enhanced options for patients that may be underserved by existing therapies. To learn more about Assertio, visit www.assertiotx.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
This news release contains forward-looking statements. These statements involve inherent risks and uncertainties that could cause actual results to differ materially from those projected or anticipated, including risks outlined in the Company's public filings with the Securities and Exchange Commission, including the Company's most recent annual report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. All information provided in this news release speaks as of the date hereof. Except as otherwise required by law, the Company undertakes no obligation to update or revise its forward-looking statements.

Investor and Media Contact:
John B. Thomas
SVP, Investor Relations and Corporate Communications
jthomas@assertiotx.com

Source: Assertio Therapeutics, Inc.